Early Repolarization Syndrome (ERS)
Details
Early repolarization syndrome is a channelopathy defined by the presence of early repolarization pattern (ERP) on ECG — J-point elevation ≥1 mm in ≥2 adjacent inferior or lateral leads — in a patient resuscitated from polymorphic VT, unexplained idiopathic VF, or with autopsy-negative SCD. Previously considered benign, ERP is now recognized as a risk factor for SCD.
Key Facts
-
ERP prevalence: ~5.8% in adults; higher in the pediatric population, physically active individuals (up to 33.9%), and Black and Southeast Asian individuals. (sources/channelopathies-jaha-2025)
-
Belongs to the J-wave syndrome spectrum alongside Brugada syndrome. (sources/channelopathies-jaha-2025)
-
Genetics: Most studied mutation is gain-of-function in KCNJ8 (Kir6.1 subunit of KATP channel). ABCC9 (SUR2A, KATP current) also linked. Loss-of-function mutations in Ca²⁺ channels (CACNA1C, CACNB2, CACNA2D1) and Na⁺ channels (SCN5A, SCN10A) also implicated (Table 6). (sources/channelopathies-jaha-2025)
-
Initial presentation is often a life-threatening arrhythmia; frequently discovered incidentally on ECG. (sources/channelopathies-jaha-2025)
-
Diagnosis: ERS diagnosed when resuscitated polymorphic VT/IVF + ERP on ECG, or autopsy-negative SCD + ERP. Shanghai Score System used for probability stratification (≥5 pts = probable/definite ERS). (sources/channelopathies-jaha-2025)
-
Asymptomatic ERP: Guidelines state no further testing or treatment required. (sources/channelopathies-jaha-2025)
-
High-risk features: Inferolateral ERP with horizontal/downsloping ST segments, recurrent syncope, family history of SCD — may benefit from ILR or EPS. (sources/channelopathies-jaha-2025)
-
Management: ICD for survivors of sudden cardiac arrest. Pharmacotherapy: quinidine (suppresses Ito-driven VF), isoproterenol (restores epicardial AP dome via Ca²⁺ channel current), PDE-III inhibitors — cilostazol/milrinone (inhibit Ito, augment ICa,L, reverse phase 2 reentry). (sources/channelopathies-jaha-2025)
-
Emerging: VF Mapping trial (NCT03764592): noninvasive electrocardiographic imaging to identify VF substrates for ablation in BrS/ERS. ARumenamide-787 shows promise for J-wave syndromes. (sources/channelopathies-jaha-2025)
-
ESC 2022 guideline recommendations:
- ERP defined as J-point elevation ≥1 mm in ≥2 adjacent inferior and/or lateral ECG leads: Class I. (sources/VA-SCD-ESC-2022)
- ERS diagnosed in patient resuscitated from unexplained VF/PVT with ERP: Class I. (sources/VA-SCD-ESC-2022)
- ICD after SCA: Class I (Level B). (sources/VA-SCD-ESC-2022)
- In SCD victim with negative autopsy + antemortem ECG demonstrating ERP: consider ERS diagnosis Class IIa. (sources/VA-SCD-ESC-2022)
- First-degree relatives of ERS patients: clinical evaluation for ERP with high-risk features: Class IIa. (sources/VA-SCD-ESC-2022)
- ILR in individuals with ERP + ≥1 risk feature or arrhythmic syncope: Class IIa. (sources/VA-SCD-ESC-2022)
- Isoproterenol for ERS electrical storm: Class IIa. (sources/VA-SCD-ESC-2022)
- Quinidine + ICD for recurrent VF: Class IIa. (sources/VA-SCD-ESC-2022)
- PVC ablation for recurrent VF triggered by similar PVC unresponsive to medical treatment: Class IIa. (sources/VA-SCD-ESC-2022)
- High-risk ERP features: J waves >2 mm, dynamic changes in J-point and ST morphology. (sources/VA-SCD-ESC-2022)
- Routine clinical evaluation in asymptomatic subjects with ERP: NOT recommended (Class III). (sources/VA-SCD-ESC-2022)
- ICD in asymptomatic patients with isolated ERP: NOT recommended (Class III). (sources/VA-SCD-ESC-2022)
Contradictions / Open Questions
- Asymptomatic ERP: 5.8% prevalence but very low absolute SCD risk — counseling gap: ERP is present in ~5.8% of adults and is the majority finding in ERS diagnostics. Yet ERS causing SCD is rare. No clinical algorithm accurately identifies which asymptomatic individuals with ERP will progress to ERS. Guidelines explicitly recommend against further testing in asymptomatic ERP (Class III), but the discovery of ERP on routine ECGs frequently triggers patient anxiety and physician uncertainty that guidelines do not adequately address. (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- J-wave syndrome overlap with BrS — shared pathophysiology, divergent management implications: ERS and BrS share the Ito-driven phase 2 reentry mechanism and are considered J-wave syndrome partners. Yet their management protocols differ, genetic profiles differ, and drug responses differ (quinidine is first-line in both but isoproterenol is ERS/BrS-specific). The classification of a given patient as ERS vs. BrS has significant management and prognostic consequences, yet the boundary between overlapping J-wave syndromes is not precisely defined in current guidelines. (sources/channelopathies-jaha-2025, sources/VA-SCD-ESC-2022)
- ERP in athletes — benign adaptational change vs. low-level disease: High-prevalence ERP in physically active individuals (up to 33.9%) raises the question of whether athletic ERP represents a benign autonomic/vagal adaptation or is a subclinical form of the same pathophysiology. No prospective data define the SCD risk of ERP in elite athletes vs. sedentary individuals with ERP, which complicates athletic eligibility decisions. (sources/channelopathies-jaha-2025)
Connections
- Related to concepts/Cardiac-Action-Potential
- Related to concepts/Shanghai-Score-System
- Related to concepts/Sudden-Cardiac-Death
- Related to concepts/Ion-Channel-Mutations
- Related to entities/Brugada-Syndrome
- Related to entities/Short-QT-Syndrome
- Related to entities/Idiopathic-Ventricular-Fibrillation
- Related to concepts/Electrical-Storm